Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 177Lu-DOTATATE receptor radionuclide therapy in somatostatin receptor-positive tumors
2011-002891-18Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Feb 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET), endocrine neoplasm (NET), breast cancer and 4 more, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Disease control rate. Started Feb 2012; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)endocrine neoplasm (NET)breast cancersmall cell lung cancer (SCLC)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2011-002891-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002891-18.